NYSE:HSP Hospira (HSP) Stock Price, News & Analysis → “The Stock Market’s Bull Run is Far from Over” -Barrons (From Vertical Research Advisory) (Ad) Free HSP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Hospira alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Hospira Stock (NYSE:HSP)Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… HSP Stock News HeadlinesOctober 6, 2023 | msn.comMental health coaching can help bridge the gap in provider shortage in KansasApril 20, 2023 | theguardian.comThe ‘missing personality type’: could you be a Highly Sensitive Person?March 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!March 21, 2023 | proactiveinvestors.comHealthLynked awarded patent for "Secure Patient Access via Healthcare Service Provider Specific Wireless Access Point”February 11, 2023 | yahoo.comThose who invested in Hargreaves Services (LON:HSP) three years ago are up 65%February 10, 2023 | thestreet.comHospira Stock Falls On Unusually High Volume (HSP)January 17, 2023 | msn.comSikkim didn't get due share of development, bring HSP to power for real change: Bhaichung to peopleJanuary 9, 2023 | finanznachrichten.deGo Metals Corp.: Go Metals Results from PGE Zone Nickel-Copper SulphideMarch 29, 2024 | Vertical Research Advisory (Ad)“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!January 9, 2023 | ca.finance.yahoo.comGo Metals Results from PGE Zone Nickel-Copper SulphideDecember 6, 2022 | finance.yahoo.comGo Metals Initial Drill Results from PGE Central ZoneDecember 5, 2022 | juniorminingnetwork.comGo Metals Announces Initial Drill Results from PGE Central ZoneOctober 25, 2022 | proactiveinvestors.comFalcon Gold expands its HSP south project in southern Quebec by 70%August 26, 2022 | finance.yahoo.comBiotechnology Traded below Moving Averages in Last Week of AugustJune 21, 2022 | nz.finance.yahoo.comDalrada Financial Corporation Appoints Brian McGoff as President and Chief Operating OfficerMay 3, 2022 | thestreet.com5 Stocks Setting New 52-Week HighsFebruary 22, 2022 | thestreet.com'Mad Money' Lightning Round: BorgWarner Is a BuyJanuary 14, 2022 | thestreet.comHospira (HSP) Stock Spikes Today on $17 Billion Pfizer MergerOctober 26, 2021 | finance.yahoo.comDollar hits Pfizer; Merck 'blew away' estimatesAugust 19, 2021 | apnews.comConduent To Provide Advanced Claims Administration Solution to Help Eastpointe Health Deliver ...See More Headlines Receive HSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hospira and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/29/2015Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryPharmaceuticals Current SymbolNYSE:HSP CUSIP44106010 CIK1274057 Webwww.hospira.com Phone+1-847-9376472FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report HSP Stock Analysis - Frequently Asked Questions How were Hospira's earnings last quarter? Hospira Inc (NYSE:HSP) announced its quarterly earnings results on Wednesday, July, 29th. The healthcare company reported $0.85 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.78 by $0.07. The healthcare company earned $1.20 billion during the quarter, compared to analysts' expectations of $1.18 billion. The company's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.72 earnings per share. What other stocks do shareholders of Hospira own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hospira investors own include Gilead Sciences (GILD), Johnson & Johnson (JNJ), Thermo Fisher Scientific (TMO), Twitter (TWTR), Allergan (AGN), Bank of America (BAC), Citigroup (C), Costco Wholesale (COST), Chevron (CVX) and Express Scripts (ESRX). This page (NYSE:HSP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hospira Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.